

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

01 AUG 13 PM 9:10

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Aventis Pharma AG			
2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue, NW, Suite 725			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20004			
4. Contact Name Eddie D. Evans	Telephone 202-898-3182	E-mail (optional)	5. Senate ID # 56838-17
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 3518600

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_

11. No Lobbying Activities

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSES</b> relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>1.3M</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description.
	<input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition
	<input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6113 Internal Revenue Code
	<input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

LD-2 (REV. 6/98)



Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the client was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- S. 1191 "Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations Act, 2002"
- H.R. 2330 "Agriculture, Rural Development, Food and Drug Administration and related Agencies Appropriations Act, 2002"

All provisions relating to the reimportation of prescription drugs.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie D. Evans	
Donald Zowader	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA, headquartered in Strasburg France is the parent company of Aventis Pharmaceuticals. Aventis Pharmaceuticals is interested because of the potential negative effect this legislation could have on public health.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Page



Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the client was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific lobbying issues

S. 812 "Greater Access to Affordable Pharmaceuticals Act of 2001"

H.R. 1862 "Greater Access to Affordable Pharmaceuticals Act of 2001"

All provisions.

17. House(s) of Congress and Federal agencies contacted  
House of Representatives and Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie D. Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis Pharma, a subsidiary of Aventis SA is interested in this legislation because it would upset the delicate balance in the Drug Price Competition and Patent Restoration Act of 1984

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Page



Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific lobbying issues

S. 754 "Drug Competition Act of 2001"

All provisions.

17. House(s) of Congress and Federal agencies contacted  
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie D. Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is the parent company of Aventis Pharmaceuticals. Aventis is interested in ensuring that the objectives of this legislation are achieved and unintended consequences minimized.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form 1.D-2 (Rev 6/98)

Page



Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

S. 838 "Best Pharmaceuticals for Children Act"

All provisions.

17. House(s) of Congress and Federal agencies contacted  Check if None  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
Aventis SA is the parent company of Aventis Pharmaceuticals. Aventis is interested in renewing the incentive to conduct pediatric research.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form I.D-2 (Rev 6/98)

Page



Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S.826 "Improved Access to Osteoporosis Testing Act of 2001"

H.R. 1720 "Improved Access to Osteoporosis Testing Act of 2001"

All provisions relating to the elimination of the cost sharing for BMD s for Medicare beneficiaries that have a high risk for osteoporosis.

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Donald Zowader	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Aventis SA is the parent company of Aventis Pharmaceuticals. Aventis is interested in this legislation because it could lead to early detection of individuals with osteoporosis.

Signature Eddie H. Evans

Date Aug 10, 2001

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Page

